SAN JOSE, Calif.--(BUSINESS WIRE)--HighTech Business Decisions has just published its new study: “Biopharmaceutical Contract Manufacturing: Best Practices Pricing Study 2016.” This 350-page report details both the prices paid by biotechnology companies and prices charged by biopharmaceutical contract manufacturing organizations for large-molecule drug substance production, using both mammalian cell culture and microbial fermentation technologies, at specific bioreactor tank sizes. In addition, this report documents current prices for other services offered by the contract manufacturing organizations, including cell banking, cell-line development, process development, technology transfer, and regulatory support.
William Downey, president of HighTech Business Decisions, explained, “According to the biotechnology and contract manufacturing executives, overall contract manufacturing prices have shown a moderate increase over the past two years as industry supply and demand come into balance. Furthermore, contract manufacturing organizations see higher demand, greater capacity—especially disposable bioreactors, and added regulatory and quality requirements will affect industry pricing. Going forward, most biotechnology executives expect to pay higher prices for production, analytical and development services, and stability and release testing.”
This report provides the reader with over 225 detailed charts and tables covering industry trends, prices, and selected contract terms such as reservation and cancellation fees, change orders, price models and arrangements. In addition to production prices, this report also documents FTE rates paid and charged by major functional areas.
About HighTech Business Decisions
HighTech Business Decisions is a market research and consulting firm specializing in biopharmaceutical contract manufacturing. The company has been producing in-depth public reports and customized benchmarking, market analysis and customer loyalty programs for over fifteen years. Visit us at www.hightechdecisions.com.